The importance of hapten-protein complex formation in the development of drug allergy

Current Opinion in Allergy and Clinical Immunology

Volumn 14, Issue 4, 2014, Pages 293-300

  Faulkner, Lee ^a   Meng, Xiaoli ^a   Park, B Kevin ^a   Naisbitt, Dean J ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

antigen; drug allergy; hapten; pi concept; T cells

Indexed keywords

ABACAVIR; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAMAZEPINE; HAIR DYE; HUMAN SERUM ALBUMIN; MEROPENEM; NEVIRAPINE; PENICILLIN DERIVATIVE; PHENYLENEDIAMINE; SULFAMETHOXAZOLE; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 4-PHENYLENEDIAMINE; BETA LACTAM; HAPTEN; PHENYLENEDIAMINE DERIVATIVE; SULFONAMIDE;

ANTIGEN STRUCTURE; DRUG HYPERSENSITIVITY; DRUG SENSITIZATION; HAPTEN CARRIER COMPLEX; HUMAN; METABOLITE; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; ANTIGEN PRESENTATION; IMMUNOLOGY; T LYMPHOCYTE;

ANTIGEN PRESENTATION; BETA-LACTAMS; DIDEOXYNUCLEOSIDES; DRUG HYPERSENSITIVITY; HAPTENS; HUMANS; PHENYLENEDIAMINES; SULFONAMIDES; T-LYMPHOCYTES;

EID: 84903791930     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0000000000000078     Document Type: Review

References (64)

1. Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004; 13:832-836.
2. Gentile I, Talamo M, Borgia G. Is the drug-induced hypersensitivity syndrome (DIHS) due to human herpesvirus 6 infection or to allergy-mediated viral reactivation? Report of a case and literature review. BMC Infect Dis 2010; 10:49-53.
3. Picard D, Janela B, Descamps V, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. Sci Transl Med 2010; 2: 46ra62.
4. Sanderson JP, Naisbitt DJ, Park BK. Role of bioactivation in drug-induced hypersensitivity reactions. AAPS J 2006; 8:E55-E64.
5. Coulter EM, Farrell J, Mathews KL, et al. Activation of human dendritic cells by p-phenylenediamine. J Pharmacol Exp Ther 2007; 320:885-892.
6. Elsheikh A, Lavergne SN, Castrejon JL, et al. Drug antigenicity, immunogenicity, and costimulatory signaling: evidence for formation of a functional antigen through immune cell metabolism. J Immunol 2010; 185:6448-6460.
7. Zhang X, Sharma AM, Uetrecht J. Identification of danger signals in nevirapine- induced skin rash. Chem Res Toxicol 2013; 26:1378-1383.
8. Picardo M, Cannistraci C, Cristaudo A, et al. Study on cross-reactivity to the para group. Dermatologica 1990; 181:104-108.
9. Coulter EM, Jenkinson C, Wu Y, et al. Activation of T-cells from allergic patients and volunteers by p-phenylenediamine and Bandrowski's base. J Invest Dermatol 2008; 128:897-905.
10. Jenkinson C, Jenkins RE, Maggs JL, et al. A mechanistic investigation into the irreversible protein binding and antigenicity of p-phenylenediamine. Chem Res Toxicol 2009; 22:1172-1180.
11. Jenkinson C, Jenkins RE, Aleksic M, et al. Characterization of p-phenylenediamine- albumin binding sites and T-cell responses to hapten-modified protein. J Invest Dermatol 2010; 130:732-742.
12. Jahn S, Faber H, Zazzeroni R, Karst U. Electrochemistry/liquid chromatography/ mass spectrometry to demonstrate irreversible binding of the skin allergen p-phenylenediamine to proteins. Rapid Commun Mass Spectrom 2012; 26:1415-1425.
13. Pot LM, Scheitza SM, Coenraads PJ, Blömeke B. Penetration and haptenation of p-phenylenediamine. Contact Dermatitis 2013; 68:193-207.
14. Sieben S, Kawakubo Y, Al Masaoudi T, et al. Delayed-type hypersensitivity reaction to paraphenylenediamine is mediated by 2 different pathways of antigen recognition by specific alphabeta human T-cell clones. J Allergy Clin Immunol 2002; 109:1005-1011.
15. Cribb AE, Spielberg SP. Sulfamethoxazole is metabolized to the hydroxylamine in humans. Clin Pharmacol Ther 1992; 51:522-526.
16. Cribb AE, Spielberg SP, Griffin GP. N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes. Drug Metab Dispos 1995; 23:406-414.
17. Reilly TP, Lash LH, Doll MA, et al. A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions. J Invest Dermatol 2000; 114:1164-1173.
18. Roychowdhury S, Vyas PM, Reilly TP, et al. Characterization of the formation and localization of sulfamethoxazole and dapsone-associated drug-protein adducts in human epidermal keratinocytes. J Pharmacol Exp Ther 2005; 314:43-52.
19. Roychowdhury S, Vyas PM, Svensson CK. Formation and uptake of arylhydroxylamine- haptenated proteins in human dendritic cells. Drug Metab Dispos 2007; 35:676-681.
20. Sanderson JP, Naisbitt DJ, Farrell J, et al. Sulfamethoxazole and its metabolite nitroso sulfamethoxazole stimulate dendritic cell costimulatory signaling. J Immunol 2007; 178:5533-5542.
21. Cribb AE, Miller M, Leeder JS, et al. Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione. Implications for idiosyncratic toxicity. Drug Metab Dispos 1991; 19:900-906.
22. Naisbitt DJ, Hough SJ, Gill HJ, et al. Cellular disposition of sulphamethoxazole and its metabolites: implications for hypersensitivity. Br J Pharmacol 1999; 126:1393-1407.
23. Callan HE, Jenkins RE, Maggs JL, et al. Multiple adduction reactions of nitroso sulfamethoxazole with cysteinyl residues of peptides and proteins: implications for hapten formation. Chem Res Toxicol 2009; 22:937-948.
24. Manchanda T, Hess D, Dale L, et al. Haptenation of sulfonamide reactive metabolites to cellular proteins. Mol Pharmacol 2002; 62:1011-1126.
25. Naisbitt DJ, Farrell J, Gordon SF, et al. Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation. Mol Pharmacol 2002; 62:628-637.
26. Schnyder B, Burkhart C, Schnyder-Frutig K, et al. Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T cells from allergic individuals. J Immunol 2000; 164:6647-6654.
27. Burkhart C, von Greyerz S, Depta JP, et al. Influence of reduced glutathione on the proliferative response of sulfamethoxazole-specific and sulfamethoxazolemetabolite- specific human CD4+ T-cells. Br J Pharmacol 2001; 132:623-630.
28. Castrejon JL, Berry N, El-Ghaiesh S, et al. Stimulation of human T cells with sulfonamides and sulfonamide metabolites. J Allergy Clin Immunol 2010; 125:411-418; e414.
29. Elsheikh A, Castrejon L, Lavergne SN, et al. Enhanced antigenicity leads to altered immunogenicity in sulfamethoxazole-hypersensitive patients with cystic fibrosis. J Allergy Clin Immunol 2011; 127:1543-1551; e1543.
30. Chen J, Mannargudi BM, Xu L, Uetrecht J. Demonstration of the metabolic pathway responsible for nevirapine-induced skin rash. Chem Res Toxicol 2008; 21:1862-1870.
31. Wen B, Chen Y, Fitch WL. Metabolic activation of nevirapine in human liver microsomes: dehydrogenation and inactivation of cytochrome P450 3A4. Drug Metab Dispos 2009; 37:1557-1562.
32. Srivastava A, Lian LY, Maggs JL, et al. Quantifying the metabolic activation of nevirapine in patients by integrated applications of NMR and mass spectrometries. Drug Metab Dispos 2010; 38:122-132.
33. Takakusa H, Masumoto H, Yukinaga H, et al. Covalent binding and tissue distribution/retention assessment of drugs associated with idiosyncratic drug toxicity. Drug Metab Dispos 2008; 36:1770-1779.
34. Sharma AM, Klarskov K, Uetrecht J. Nevirapine bioactivation and covalent binding in the skin. Chem Res Toxicol 2013; 26:410-421.
35. Meng X, Howarth A, Earnshaw CJ, et al. Detection of drug bioactivation in vivo: mechanism of nevirapine-albumin conjugate formation in patients. Chem Res Toxicol 2013; 26:575-583.
36. Caixas U, Antunes AM, Marinho AT, et al. Evidence for nevirapinebioactivation in man: searching for the first step in the mechanism of nevirapine toxicity. Toxicology 2012; 301:33-39.
37. Lu W, Uetrecht JP. Peroxidase-mediated bioactivation of hydroxylated metabolites of carbamazepine and phenytoin. Drug Metab Dispos 2008; 36:1624-1636.
38. Pearce RE, Lu W, Wang Y, et al. Pathways of carbamazepine bioactivation in vitro. III. The role of human cytochrome P450 enzymes in the formation of 2,3- dihydroxycarbamazepine. Drug Metab Dispos 2008; 36:1637-1649.
39. Kang P, Liao M, Wester MR, et al. CYP3A4-Mediated carbamazepine (CBZ) metabolism: formation of a covalent CBZ-CYP3A4 adduct and alteration of the enzyme kinetic profile. Drug Metab Dispos 2008; 36:490-499.
40. Higuchi S, Yano A, Takai S, et al. Metabolic activation and inflammation reactions involved in carbamazepine-induced liver injury. Toxicol Sci 2012; 130:4-16.
41. Pirmohamed M, Kitteringham NR, Guenthner TM, et al. An investigation of the formation of cytotoxic, protein-reactive and stable metabolites from carbamazepine in vitro. Biochem Pharmacol 1992; 43:1675-1682.
42. Bu HZ, Kang P, Deese AJ, et al. Human in vitro glutathionyl and protein adducts of carbamazepine-10,11-epoxide, a stable and pharmacologically active metabolite of carbamazepine. Drug Metab Dispos 2005; 33:1920-1924.
43. Pearce RE, Uetrecht JP, Leeder JS. Pathways of carbamazepine bioactivation in vitro: II. The role of human cytochrome P450 enzymes in the formation of 2-hydroxyiminostilbene. Drug Metab Dispos 2005; 33:1819-1826.
44. Naisbitt DJ, Britschgi M, Wong G, et al. Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol Pharmacol 2003; 63:732-741.
45. Wu Y, Farrell J, Pirmohamed M, et al. Generation and characterization of antigen-specific CD4+, CD8+, and CD4+CD8+ T-cell clones from patients with carbamazepine hypersensitivity. J Allergy Clin Immunol 2007; 119:973-981.
46. Lichtenfels M, Farrell J, Ogese MO, et al. HLA restriction of carbamazepinespecific T-Cell clones from an HLA-A31:01-positive hypersensitive patient. Chem Res Toxicol 2014; 27:175-177.
47. Ko TM, Chung WH, Wei CY, et al. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol 2011; 128:1266-1276.
48. Wei CY, Chung WH, Huang HW, et al. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. J Allergy Clin Immunol 2012; 129:1562-1569.
49. Illing PT, Vivian JP, Dudek NL, et al. Immune self-reactivity triggered by drugmodified HLA-peptide repertoire. Nature 2012; 486:554-558.
50. Batchelor FR, Dewdney JM, Gazzard D. Penicillin allergy: the formation of the penicilloyl determinant. Nature 1965; 206:362-364.
51. Jenkins RE, Meng X, Elliott VL, et al. Characterisation of flucloxacillin and 5-hydroxymethyl flucloxacillin haptenated HSA in vitro and in vivo. Proteomics Clin Appl 2009; 3:720-729.
52. Whitaker P, Meng X, Lavergne SN, et al. Mass spectrometric characterization of circulating and functional antigens derived from piperacillin in patients with cystic fibrosis. J Immunol 2011; 187:200-211.
53. Meng X, Jenkins RE, Berry NG, et al. Direct evidence for the formation of diastereoisomeric benzylpenicilloyl haptens from benzylpenicillin and benzylpenicillenic acid in patients. J Pharmacol Exp Ther 2011; 338:841-849.
54. Jenkins RE, Yaseen FS, Monshi MM, et al. b-Lactam antibiotics form distinct haptenic structures on albumin and activate drug-specific T-lymphocyte responses in multiallergic patients with cystic fibrosis. Chem Res Toxicol 2013; 26:963-975.
55. Ariza A, Garzon D, Abánades DR, et al. Protein haptenation by amoxicillin: high resolution mass spectrometry analysis and identification of target proteins in serum. J Proteomics 2012; 77:504-520.
56. Monshi MM, Faulkner L, Gibson A, et al. Human leukocyte antigen (HLA)- B57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. Hepatology 2013; 57:727-739.
57. Wuillemin N, Adam J, Fontana S, et al. HLA haplotype determines hapten or pi T cell reactivity to flucloxacillin. J Immunol 2013; 190:4956-4964.
58. Nhim C, Delluc S, Halgand F, et al. Identification and frequency of circulating CD4 [+] T lymphocytes specific to Benzylpenicillin in healthy donors. Allergy 2013; 68:899-905.
59. Charneira C, Grilo NM, Pereira SA, et al. N-terminal valine adduct from the anti- HIV drug abacavir in rat haemoglobin as evidence for abacavir metabolism to a reactive aldehyde in vivo. Br J Pharmacol 2012; 167:1353-1361.
60. Grilo NM, Antunes AM, Caixas U, et al. Monitoring abacavir bioactivation in humans: screening for an aldehyde metabolite. Toxicol Lett 2013; 219:59-64.
61. Meng X, Lawrenson AS, Berry NG, et al. Abacavir forms novel cross-linking abacavir protein adducts in patients. Chem Res Toxicol 2014; 27:524-535.
62. Chessman D, Kostenko L, Lethborg T, et al. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity 2008; 28:822-832.
63. Ostrov DA, Grant BJ, Pompeu YA, et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci USA 2012; 109:9959-9964.
64. Norcross MA, Luo S, Lu L, et al. Abacavir induces loading of novel selfpeptides into HLA-B57:01: an autoimmune model for HLA-associated drug hypersensitivity. AIDS 2012; 26:F21-F29.